Solution Structure of ETO-TAFH refined in explicit solvent - Wei, Y.; Liu, S.; Lausen, J.; Woodrell, C.; Cho, S.; Biris, N.; Kobayashi, N.; Wei, Y.; Yokoyama, S.; Werner, M. H. (Biological Magnetic Resonance Bank, 2008)

The acute myeloid leukemia fusion protein AML1-ETO targets E-proteins via a PAH-like TAFH domain - Plevin, M. J.; Zhang, J.; Guo, C.; Roeder, R. G.; Ikura, M. (Biological Magnetic Resonance Bank, 2006)

Distinctive solution conformation of phosphatase inhibitor CPI-17 substituted with aspartate at the phosphorylation site threonine - Ohki, S.; Eto, M.; Shimizu, M.; Takada, R.; Brautigan, D. L.; Kainosho, M. (Biological Magnetic Resonance Bank, 2004)

Distinctive solution conformation of phosphatase inhibitor CPI-17 substituted with aspartate at the phosphorylation site threonine - Ohki, S.; Eto, M.; Shimizu, M.; Takada, R.; Brautigan, D. L.; Kainosho, M. (Biological Magnetic Resonance Bank, 2004)

The MYND domain from human AML1-ETO - Liu, Yizhou; Chen, Wei; Gaudet, Justin; Cheney, Matthew; Roudaia, Liya; Cierpicki, Tomasz; Klet, Rachel; Hartman, Kari; Laue, Thomas; Speck, Nancy; Bushweller, John (Biological Magnetic Resonance Bank, 2007)